Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39661064.
- Also identified by DOI 10.1073/pnas.2407910121 and PMC identifier 11665913.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Here, we show that vitamin E succinate (VES) acts as a degrader for the m<sup>6</sup>A RNA demethylase fat mass and obesity-associated protein (FTO), thus suppressing tumor growth and resistance to immunotherapy. FTO is ubiquitinated by its E3 ligase DTX2, followed by UFD1 recruitment and subsequent degradation in the proteasome. VES binds to FTO and DTX2, leading to enhanced FTO-DTX2 interaction, FTO ubiquitination, and degradation in FTO-dependent tumor cells. VES suppressed tumor growth and enhanced antitumor immunity and response to immunotherapy in vivo in mouse models. Genetic FTO knockdown or VES treatment increased m<sup>6</sup>A methylation in the LIF (Leukemia Inhibitory Factor) gene and decreased LIF mRNA decay, and thus sensitized melanoma cells to T cell-mediated cytotoxicity. Taken together, our findings reveal the underlying molecular mechanism for FTO protein degradation and identify a dietary degrader for FTO that inhibits tumor growth and overcomes immunotherapy resistance.
Medical subject headings
- Alpha-Ketoglutarate-Dependent Dioxygenase FTO
- Ubiquitin-Protein Ligases